<DOC>
	<DOC>NCT01347190</DOC>
	<brief_summary>Study to assess safety and tolerability of a single dose of study-drug administered to Cystic Fibrosis (CF) patients.</brief_summary>
	<brief_title>Safety and Tolerability Study of Liquid Alpha1 Proteinase Inhibitor (API) in Subjects With Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Have a confirmed diagnosis of CF: one or more clinical findings consistent with CF and at least one of the following: 1. Sweat chloride ≥ 60 mEq/L by quantitative pilocarpine iontophoresis test OR 2. A genotype with two identifiable mutations consistent with CF (∆F508 homozygous or two alleles known to cause a class I, II, or III mutation) Have an FEV1 ≥30% of predicted normal as defined by age, gender, and height Oxygen saturation &lt;90% Changed in treatment regimen within 2 weeks prior to screening Antibiotics regimen change &lt; 4 weeks before screening Persistent colonization with Burkholderia cepacia Serum IgA &lt; 50% of lower level of normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Cystic Fibrosis</keyword>
</DOC>